Phosphoglucomutase activity as a novel biomarker in patients with acute myocardial infarction.

Phosphoglucomutase (PGM), a key enzyme in cellular glucose utilization and energy homeostasis, has been reported to show a relationship with oxidative stress. However, the clinical importance of PGM activity has not been investigated in patients with ischemic heart disease (IHD). The aim of the present pilot study was to clarify whether PGM activity has potential as a cardiovascular risk predictor in patients with IHD. The levels of serum PGM activity in 237 patients with IHD (63 patients with acute myocardial infarction (AMI) and 174 patients with stable effort angina pectoris (EAP)) were evaluated. PGM activity was compared with levels of various myocardial, thrombosis, and inflammatory biomarkers on admission. PGM activity in the AMI group was significantly increased relative to that in the EAP group on admission (AMI, 55.5 μmol·min(-1)·L(-1) (U/L); EAP, 14.4 U/L (P<0.001)), and was observed to increase in parallel with well-established myocardial markers (P<0.001). Moreover, PGM activity and the lipid, thrombosis, and inflammatory biomarkers in the AMI group were higher than those in the EAP group. PGM activity increased with levels of myocardial, thrombosis, and inflammatory biomarkers in patients with AMI, and might be useful in diagnostic applications during the acute phase in patients with AMI.

Citation

Makoto Nishinari, Naoyoshi Aoyama, Zensuke Ogawa, Shogo Yukino, Shusaku Oka, Kouji Yano, Yoshifumi Kurosaki, Ichiro Takeuchi, Ryuta Imaki, Taiki Tojo, Takao Shimohama, Hitoshi Takehana, Tohru Izumi. Phosphoglucomutase activity as a novel biomarker in patients with acute myocardial infarction. Circulation journal : official journal of the Japanese Circulation Society. 2012;76(9):2197-203

Mesh Tags

Substances

PMID: 22785563

search → result